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L-ARGININE is converted to the highly reactive and un-
stable nitric oxide (NO) and .-citrulline by an enzyme
named nitric oxide synthase (NOS). NO decomposes into
other nitrogen oxides such as nitrite (NO) and nitrate
(NO), and in the presence of superoxide anion to the
potent oxidizing agent peroxynitrite (ONOO-). Activated
rodent macrophages are capable of expressing an in-
ducible form of this enzyme (iNOS) in response to appro-
priate stimuli, i.e., lipopolysaccharide (LPS) and
interferon-T (IFNT). Other cytokines can modulate the
induction of NO biosynthesis in macrophages. NO is a
major effector molecule of the anti-microbial and cyto-
toxic activity of rodent macrophages against certain mi-
cro-organisms and tumour cells, respectively. The NO
synthesizing pathway has been demonstrated in human
monocytes and other cells, but its role in host defence
seems to be accessory. A delicate functional balance be-
tween microbial stimuli, host-derived cytokines and hor-
mones in the microenvironment regulates iNOS expres-
sion. This review will focus mainly on the known and
proposed mechanisms of the regulation of iNOS induc-
tion, andon agents that can modulateNO release once the
active enzyme has been expressed in the macrophage.
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History and basic concepts
The history of the discovery of the L-arginine-NO
pathway is discussed only briefly, as excellent re-
views are available. 1-3 In the early 1980s, in vivo
studies demonstrated that rats, mice and humans
excrete more nitrate than they ingest, suggesting that
mammals form nitrogen oxides endogenously. 1,3 In
1987, NO was found to explain both the biological
activity of the elusive endothelium-derived relaxina
factor2-5 and the t-arginine dependent tumouricida
activity of activated murine macrophages. Th,
products of this enzymatic pathway are t-citrullin,
and the highly reactive and unstable nitric oxid,
(NO), which decomposes (after complexing witl
certain forms ’of iron, or non-enzymatically) int(
other nitrogen oxides such as nitrite (NO)
nitrate (NO-) (Fig. 1). The enzyme responsible fo
NO production has been named nitric oxide synthas,
(NON). Although evidence exists that NO is th,
primary product released by NOS, it is possible tha
NOS-containing cells produce a mixture of NO, NO:
NO, NO-, N203, nitrosamines, non-protei
nitrosothiols and S-nitrosylated proteins.
Soon after its discovery, the new metabolic path-
way was found to be t-arginine dependent.
5,9-1 NO
is synthesized from the terminal guanidino nitrogen
atom of this amino acid (and not I)-arginine), with-
out loss of the guanidino carbon atom. Although it
was initially believed that cNOS produced NO by a
different process without nucleotide-derived
cofactors, recent work now supports a general
scheme. 12 NOS incorporates molecular oxygen both
into NO and citrulline. Activated macrophages form
NO from r.o-hydroxy-t-arginine,
12 confirming the pro-
posal that this compound is an intermediate in the
biosynthesis of NO.1
LPS, IFN4 ( ,( lgluortllds
co-factors
ITHB, FAD,FMN, NADPH L-NMMA
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FIG. 1. Schematic representation of the induction of the nitric oxide medi-
ated effector pathway in rodent macrophages, and its inhibition by
glucocorticoids and arginine analogues, such as L-monomethyl-arginine (L-
NMMA). Interaction of NO with the haem group of cytoplasmic guanylate
cyclase stimulates cyclic GMP formation, while its interaction with other
haem groups, or with non-haem bound iron (Fe) can lead to cytotoxic
effects. THB, tetrahydrobiopterin.
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Soon it became clear that this metabolic pathway
exists in various cells from different embryological
origins, and that different forms of NOS can be
distinguished, based on their expression and mode
of NO release. 2,3 A first subclass consists of Ca2+- and
calmodulin dependent enzymes (cNOS), releasing
NO within seconds when calmodulin binds to the
enzyme in response to a rise of cytoplasmic Ca2+
levels upon receptor stimulation. These forms are
constitutively expressed in endothelial cells and cer-
tain neuronal cells. The NO produced by these cells
acts as an inhibitory signal: it stimulates a cytoplasmic
guanylate cyclase, and cyclic GMP is formed as sec-
ond messenger. The second subclass (iNOS) con-
sists of inducible, Caa+-independent enzymes, which
can be expressed in most nucleated cells, including
rodent macrophages, following induction with
cytokines. 2,14 t-Homoarginine can serve as a substrate
for iNOS, but not for cNOS. 2’15
Recently, NOS has been purified and cloned16,22
from cerebellum, endothelium, rodent macrophages
and human hepatocytes (reviewed by Nathan3). NOS
has a close homology to cytochrome P450 reductase.17
The biochemical and molecular biological reports on
NOS result in a confusing synopsis with respect to a
scale of variables: specific activity, K for t-arginine,
relative dependence on Ca2+ and co-factors,
subcellular distribution or the gene regulating the
expression of this enzyme. Until the cloning from
additional cells and species and the use of antibody
probes clarify the systematics of the various forms of
NOS, the division into two subclasses (cNOS and
iNOS) can be retained as the most useful one.
The murine iNOS macrophage enzyme displays
approximately 50% sequence homology to the cNOS
of neuronal origin. 19 Macrophage iNOS mRNA is
strikingly inducible and it is absent in quiescent
macrophages. Like neuronal NOS, macrophage NOS
has recognition sites for FAD, FMN and NADPH and
has a consensus calmodulin binding site. 18-22
Calmodulin binds tightly as a subunit to iNOS, which
explains why iNOS is Ca2+ independent, in contrast
tO cNOS.2
Macrophages from the cloned macrophage cell
line RAW264.7 from Albeson leukaemia virus-in-
duced BALB/c lymphocytic lymphoma are rather
exceptional as they also express cNOS activity, which
is Ca2+ dependent and decreases after activation with
IFNy or LPS, or with increasing passage number. ’4
Many studies have shown that iNOS expression in
macrophages is tightly regulated by a delicate bal-
ance between microbial stimuli, host-derived
cytokines and hormones in the micro-environment.
This review will therefore focus on the known and
proposed mechanisms of the regulation of iNOS
expression in macrophages and on the agents that
can modulate NO release in these cells.
Functions of nitric oxide in host defence
Nitric oxide is a major effector molecule of the anti-
microbial and cytotoxic activity of rodent
macrophages against intracellularly growing mi-
crobes, some extracellular parasites,25,26 viruses27,28
and.some tumours. Haem proteins, proteins contain-
ing non-haem Fe and DNA are the molecular targets
of NO in cells in general and in tumour cells in
particular.
1, These interactions have many conse-
quences in the target cell: decreased protein synthe-
sis,29’3 inhibition of ribonucleotide reductase and
hence DNA synthesis, suppression of mitochondrial
respiration and aconitase of the citric acid cycle,,,25
modulation of the post-transcriptional regulation of
genes involved in iron homeostasis,31 activation of
RNA binding by an iron regulatory factor,2,3 the
suppression of antibody synthesis34 and inhibition of
T-cell proliferation. 35 NO can also combine with
superoxide anion to form the potent oxidizing agent
peroxynitrite (ONOO-). It is interesting to observe
that macrophages, the prototypical effector cells for
NO-mediated cytotoxicity, are themselves targets for
NO or peroxynitrite, as they die prematurely in cul-
ture when activated to express iNOS, a process that
appears to be mediated through apoptosis.
:,38
Moreover, NOS activity in macrophages is associated
with glucose depletion, glycolysis and hexose
monophosphate shunt activity, a decreased flux of
glucose through the tricarboxylic acid cycle and
the induction of glucose-6-phosphate dehydro-
genase.9,4 These results demonstrate that energy
metabolism in macrophages can, to a significant
extent, be determined by products of iNOS. A regu-
latory loop exists between iron metabolism and NO
in macrophages, as the addition of iron to
macrophages incubated with LPS/IFNy significantly
reduces their ability to produce NO.4
Induction of NOS in monocytes or tissue
macrophages in vivo has been demonstrated or sug-
gested by indirect measurements in several animal
models. These include intravenous injection of
LPS, 42’43 oral endrin administration to rats,
44 IgA im-
mune-complex vasculitis of the lung,45 tracheal
bleomycin instillation,4 diabetes,4 treatment with
cytotoxic drugs,48’49 exposure to benzene5 or inhala-
tion of ozone.5 The role of endogenous NO in
inflammation is still unclear. An inhibitor of NOS
activity enhanced neutrophil adhesion to endothelial
cells and their subsequent extravasation by
upregulation of the expression of the CDll/CD18
integrin on the neutrophil,52 suggesting that en-
dogenous NO continuously suppresses neutrophil
adhesion. In contrast, the same inhibitor blocked
neutrophil-dependent injury of the pulmonary
vasculature45 and the oedema induced by intradermal
injection of substance p.5 The pro- and anti-inflam-
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matory activity of endogenous NO deserves further
investigation in different experimental settings.
Atherosclerosis and iNOS
Oxidatively modified low-density lipoprotein
(oxLDL) is taken up by macrophages via unregulated
receptor-mediated endocytosis.54 The lipid-laden
macrophages are transformed to foam cells, which
are present in early atherosclerotic lesions.
Macrophages are capable of accelerating LDL oxida-
tion in vitro. NO, particularly when generated in the
presence of superoxide anion, can oxidize LDL as
well, since the highly reactive peroxynitrite is gener-
ated. 36 However, NO synthesis by macrophages is
not required for macrophage-mediated oxidation of
LDL in vitro. On the contrary, it seems to exert a
protective role in preventing oxidative LDL modifica-
tion by macrophages. 55-57 It has been proposed that
NO can inhibit LDL oxidation by acting as a chain-
breaking anti-oxidant that is capable of scavenging
carbon-centred and peroxyl radicals. 58
Moreover, uptake of oxLDL, but not the acetylated
form, by macrophages has been shown to modulate
iNOS activity. OxLDL may prime the macrophage for
enhanced, presumably prostaglandin-mediated NO
biosynthesis, as assessed by nitrite and citrulline
accumulation in the supernatant. 59 On the other
hand, it suppresses iNOS activity resulting from
stimulation with LPS or IFN.
6-2 Addition of the
glucocorticoid receptor antagonist mifepristone did
not prevent the oxLDL dependent iNOS inhibition,
indicating that the glucocorticoid receptor is not
involved in the suppressive effect of oxLDL.3 Failure
to detect NO production by those macrophages ap-
pears to result from lack of NO synthase activity.4
Recent evidence suggests that iNOS activity, which
is normally not present in the arterial wall, is ex-
pressed when macrophage-rich lesions develop. The
cholesterol-induced formation of foam cell-rich fatty
streaks in the rabbit aorta leads to the induction of
a non-endothelial NOS.5 Furthermore, balloon
angioplasty and denudation of, respectively, rabbit6
and rat7 carotid artery, which induces intimal thick-
ening with a prominent influx of macrophages, is
accompanied by induction of NOS activity. Yet this
does not prove that macrophages are the source of
NO, since iNOS can be induced in smooth muscle
cells as well. The continuous NO release leads to
hyporeactive contractile responses, but its conse-
quences for the development of atherosclerotic le-
sions remain to be determined.
Induction of iNOS in rodent macrophages
Direct inducers: A first, critical level of regulation
consists of the induction process, since iNOS is
normally not expressed in resting macrophages. LPS,
the major constituent of the outer wall of Gram-
negative bacteria8 and IFNy: are potent inducers of
iNOS, and therefore often employed to elicit NO
biosynthesis in macrophages. Contamination with
the omnipresent LPS can thus be a serious and
complicated technical problem when studying the
regulation of iNOS activity. Other bacterial products,
such as exotoxins of Gram-positive bacteria, toxic
shock syndrome toxin-l, enterotoxin B and
lipoteichoic acid,9-1 high molecular weight material
derived from Mycoplasmafermentans2 and synthetic
analogues of the N-terminal part of bacterial
lipoprotein: are direct inducers of iNOS in
macrophages as well. A few cytokines, such as
IFN,7,74 and migration inhibitory factor (MIF)5 can
directly activate macrophages to synthesize NO.
Other inducers include Ca2+ ionophore, which both
induces and enhances the potency of LPS to induce
NOg production,: certain antitumour agents such as
flavone-8-acetic acid,7 certain food proteins,
8,9 as-
bestos fibres,
8 stable analogues of cyclic AMP1 (see
subsequent section), monoclonal antibodies to MHC
II antigens
2 and membrane fragments of tumour
cells,s
In primary mouse peritoneal macrophages, LPS
and IFNy only caused significant biosynthesis of
nitrogen oxides when the cells were elicited by
thioglycolate broth or pretreated with Bacillus
Calmette-Gurin. Based on these experiments with
mouse cells, it appears that macrophage activation
for cytotoxicity requires two exogenous signals: one
signal primes or sensitizes the cell, the second acti-
vates it for killing and production of NO. 1’8 In
rats, however, resident alveolar and peritoneal
macrophages produce NO in response to relatively
low doses of a single exogenous activating stimulus,
including LPS.84’85 Moreover, the macrophage activa-
tion process may differ between mouse strains,
6 and
appears to be age-dependent. The ability of cultured
macrophages to secrete nitrogen oxides correlates
with the age of the mice from which they are har-
vested. IFNy-induced release of NO is 50% lower in
macrophages taken from old mice than from young
mice.8
Signal transduction: The induction of NOS in
macrophages requires protein synthesis. 2,,9,11 When
added during the induction phase, inhibitors ofADP
ribosylation are also able to inhibit nitrite produc-
tion.8,9 Certain protein synthesis inhibitors can trig-
ger an immediate early gene response and efficiently
activate transcription of iNOS.9 The mRNA for iNOS
shares some features with mRNA of cytokines such
as the transient expression and decay of its mRNA
(half-life of approximately 6 h) which can be pre-
vented by protein synthesis inhibition.91 The signal
transduction pathway by which IFNy induces iNOS
expression remains to be established. Experimental
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evidence suggests the involvement of G-proteins and
phospholipase C. Experiments with the Gi-protein
inhibitor pertussis toxin suggest that LPS stimulates
tumour necrosis factor-0t (TNF00 and NO production
in mouse peritoneal macrophages through different
biochemical pathways, but the signal transduction
for both pathways is regulated by a pertussis toxin-
sensitive factor,92’93 presumably a Gi-protein. NO
biosynthesis is dose-dependently reduced by protein
kinase C inhibition and induced by phorbol esters,
activators of protein kinase C,94 as well as by
translocation of protein kinase C via activation of the
membrane protein CD53, providing evidence that
protein kinase C is involved in iNOS induction.95,96
Analysis of diacylglycerol synthesis provided direct
evidence that NO synthesis in macrophages involves
the activation of an unusual phosphatidylcholine-
specific phospholipase C.97 However, tyrosine
phosphorylation may also participate in the induc-
tion of NOS, as protein tyrosine kinase inhibitors (of
the tyrophostin AG 126 family) protect mice against
LPS-induced lethal toxicity, correlating with the abil-
ity of these agents to block LPS-induced NO produc-
tion in macrophages.98,99 Macrophages from mice
with a targeted disruption of the IFN regulatory factor
1-gene produced very little NO.1 The promotor of
the murine iNOS gene contains an NF-kappa B site,
designated NF-kappa Bd. Pyrrolidine dithio-
carbamate, an inhibitor of NF-kappa B, blocks both
the activation of NF-kappa Bd-binding proteins and
NO biosynthesis in LPS-treated macrophages. 11,12
tion,92 a mechanism refractory to pertussis toxin. Pre-
exposure of peritoneal macrophages to low concen-
trations of LPS also suppresses the subsequent induc-
tion of iNOS by IFN,. These findings suggest that
preactivation of pathways normally contributing to
synergistic induction of NOS may deplete
macrophages of factors needed for its expression.
19
Regulation of NOS in vivo may therefore dependon
the relative tempo with which the inflammatory and
immune responses evolve. Reduced NO production
by macrophages exposed to LPS has also been
shown to markedly reduce the ability of
macrophages to kill the intracellular parasite
Leishmania major. This endotoxin tolerance may
represent an important means of regulation of NO
synthesis and thus a survival mechanism for
intracellular parasites.
11
Phagocytosis itself may cause upregulation of
iNOS induction. Phagocytosis of Leishmania enrietti
promastigotes or latex beads by murine macrophages
enhanced IFN,-stimulated nitrite production and
could be an important mechanism of up-regulating
their microbicidal activity.
11 Ingestion of zymosan,
but not of latex beads or silica, also acted
synergistically with LPS to induce iNOS activity.
112
These results demonstrate that phagocytosis, al-
though capable, is not always sufficient to provide an
additional signal for the induction of iNOS in mouse
macrophages. In rat macrophages opsonized
zymosan induced nitrite production in the absence
of further stimuli.85
Interactions between stimuli: Bacterial LPS interacts
synergistically with IFN, to induce NOS when both
stimuli are added together.8,74,13 A recombinant NHi-
terminal fragment of bactericidal/permeability-in-
creasing protein, which binds to LPS in the outer
membrane of Gram-negative bacteria, was shown to
inhibit murine macrophage nitric oxide production
elicited by LPS plus IFN{,
TM while the rabbit plasma
LPS-binding protein, which enhances binding and
functional responses to LPS, enhanced this NO pro-
duction.15 The elevated expression of iNOS mRNA
after co-stimulation has been shown to be due to
increased stability by some investigators, but due to
a much higher rate of transcription of the NOS gene
by others.4,16 This synergism of LPS can be mim-
icked by a monoclonal antibody directed against the
73 kDa LPS receptor on murine leukocytes,1 which
identifies this 73 kDa protein as a receptor that
mediates LPS-induced changes in macrophage NO
production. IFN, has been identified as the major
priming factor when IFN,, LPS and TNF0t are added
together to the macrophage.
1
Another regulatory mechanism is the observation
that pretreatment of macrophages with low doses of
LPS can selectively reprogram these cells, i.e., down-
regulate for subsequent LPS-activated NO produc-
Autocrine andparacrine regulation by TNF: Conflict-
ing results have been reported on the ability ofTNF
to induce NOS in murine macrophages. Some
authors reported substantial amounts of nitrite in
supernatants of mouse macrophages stimulated with
this cytokine alone.3 Others did not find TNF0 or
TNF to induce NO production by itself, but TNF is
believed to serve as an autocrine signal for cytokine
induced NO production in murine macrophages.
Endogenously produced TNF is also involved in the
induction ofNO effector mechanisms when muramyl
dipeptide (MDP),1 a bacterial wall constituent, or
Leishmania promastigotes
1 are added as co-stimuli
with IFN,. For Leishmania and Toxoplasma, the
parasite itself participates in the regulation of NO
production by macrophages through autocrineTNF
induction by the parasite: NO synthesis by IFN,
treated cells can be blocked by monoclonal antibod-
ies to TNFO114-1 and TNF0t potentiates the ability of
IFN, to reduce the development of cutaneous
Leishmaniasis in vivo via an L-arginine dependent
pathway.
17,118 These results are in agreement with the
results obtained with lymphokines in the activation
of macrophages against trypanosomes: T-cell derived
TNF0t and IFN, synergistically activate mouse
macrophages for the killing of intracellular
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Trypanosoma cruzi through an NO-mediated mecha-
nism. 119 The complement subcomponent Clq may be
involved in the modulation of autocrine binding of
TNF for subsequent generation of cytotoxic NO:
pretreatment of macrophages with 3,4,-dehydro-),t-
proline, an inhibitor of Clq secretion, suppresses
lipid A-induced activation for cytotoxicity which
correlates with a decreased NO production and re-
duction in their capacity to bind TNF.12 The role of
TNF in macrophage-mediated cytotoxicity is thus not
limited to its lytic action on certain target cells, but
TNF also acts with IFN, as an autocrine
immunomodulator to elicit the conversion of t-
arginine into nitrogen oxides. 121
In addition, paracrine effects of TNF have been
documented. TNF{x or TNF[ fail to induce NO pro-
duction by themselves, but addition of either
cytokine to IFN, increased nitrite production com-
pared with IFN, alone. 74,122 In contrast to the
paracrine effects ofTNF in murine macrophages, TNF
exerts no or only a small enhancing effect on IFN,-
induced NO production by resident rat
macrophages.84,123
Synergy with ot and interferons: IFNot or IFN, in
combination with LPS, also raised LPS-induced nitrite
production.74 A monoclonal antibody specific for
IFN[ inhibited LPS-induced NO production in
thioglycolate-elicited peritoneal macrophages, which
supports the concept that IFN[ also provides an
essential signal for LPS-triggered NO production by
mouse macrophages.
24 However, neither IFN[ nor
TNF{x, alone or in combination, triggered NO pro-
duction, demonstrating again that these macrophage-
derived cytokines, while necessary, are by them-
selves not sufficient to induce iNOS in these murine
cells.
Other stimulating cytokines: Granulocyte-
macrophage colony stimulating factor (GM-CSF)-
elicited, bone marrow-derived mouse macrophages
required only LPS for effective killing of K562 cells,
but produced little nitrite in response to LPS, unless
treated with IFN,. Conversely, macrophage colony
stimulating factor CSF-l-elicited bone marrow
macrophages required the classical IFN, plus LPS
treatment protocol to become tumouricidal, but se-
creted nitrite in response to high concentrations of
LPS alone. 25,126 Moreover, GM-CSF, but not CSF-1-
derived macrophages, showed an L-arginine depend-
ent Listeriacidal activity. Macrophage colony stimu-
lating factor- and GM-CSF-derived bone marrow
macrophages treated with cisplatin are effective in
the production of NO and the generation of
tumouricidal activity.
127 GM-CSF is also an efficient
enhancer and primer of iNOS activity in rat alveolar
macrophages. 123
When interleukin-2 (IL-2) was combined with IFN,
and TNF, there was a marked cooperative induction
of mRNA and iNOS enzyme activity in murine
peritoneal macrophages. This cooperation was truly
synergistic, as the full combination was many times
more effective than the individual agents or paired
combinations. As it required protein synthesis, the
intermediate expression of new gene products is
suggested.
128 Indeed, endogenous production of
TNF was required for this cooperative effect of IL-
2 on IFN,-induced NO production and tumour cell
lysis. 129 Moreover, certain susceptible tumour targets
constitutively produce one or more soluble recogni-
tion factors that synergize with the natural cytokines
IFN, and IL-2 to render macrophages cytotoxic for
the target cell.1
A recombinant form of human MIF, a lymphokine
produced by antigen-stimulated lymphocytes which
suppresses macrophage migration in vitro, induced
murine macrophages to express iNOS and to pro-
duce high levels of NO.:5 However, another group
reported that MIF-mediated migration inhibition was
not accompanied by endogenous production of NO
or TNF.11 Inhibition of murine macrophage migra-
tion was also triggered by lipid A, the lipid moiety of
LPS, after priming with IFN,, whereas neither MIF nor
IFN, inhibited migration when given alone.TM Prim-
ing with IFN, induced the biosynthesis of NO and
TNF. This resembled the effects of IFN, on the
induction of NO-dependent tumour cytotoxicity in
mouse macrophages, which requires autocrine
stimulation by TNF as well.
Inhibitory cytokines: IL-4, IL-10, IL-13, transforming
growth factor-[ (TGF[) and macrophage deactivat-
ing factor have been shown to inhibit the induction
of NO production in macrophages.TM The effects
of these cytokines on macrophage function are more
complex than previously recognised. IL-4 is able to
inhibit NO synthesis by IFN,-stimulated murine
peritoneal1 and adherent splenicTM macrophages,
while evidence has also been presented for syner-
gism between IL-4 and IFN, for the induction of the
t-arginine-dependent killing of Leishmania major
amastigotes.19 The repression of iNOS induction and
NO biosynthesis by IL-10 is effective only when cells
are pretreated with this cytokine35 and the mecha-
nism of this action was identified as inhibition of
endogenous TNF0t production.
14 IL-10 also has,
however, the capacity to enhance the early produc-
tion of NO by macrophages co-stimulated with IFN,
and exogenous TNFO. 141 These data support the
notion that the cytokines IL-4 and IL-10, secreted by
the Th2 lymphocyte subset, might modulate NO syn-
thesis induced by IFN,, an effector of Thl cells. 142
Moreover, the combination of sub-optimal concen-
trations of any two of the cytokines IL-4, IL-10 and
TGFI gave a potent synergistic effect on the suppres-
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sion ofNO production and killing of schistosomes by
IFN,-treated macrophages.14
TGF[ inhibited NO synthesis in IFN,-activated
murine macrophages, but only at high concentra-
tions (100 ng/ml), 132,144,145 while it enhanced iNOS
induction in 3T3 fibroblastic cells.46 On the other
hand induction of iNOS by MIF is highly sensitive to
the inhibitory effect of TGF[. This observation is a
further indication that macrophage activation by IFN,
and MIF occurs through different signalling path-
ways.75 TGF[ has been demonstrated to reduce NOS
specific activity and protein in both cytosolic and
particulate fractions, to reduce iNOS mRNA and
translation by decreasing the stability of mRNA, and
by degrading the NOS protein. 147
Monocyte chemotactic protein 1, a potent
chemoattractant for monocytes, is able to inhibit the
production induced by LPS and IFN, in a dose-
dependent manner, but this effect is only achieved
when the cells are pretreated with the chemo-
attractant. 148
Up-regulation by miscellaneous agents: Elevated tem-
perature may contribute to enhanced host defence
by accelerating and amplifying the induction of NO
synthesis in macrophages. 149 Picolinic acid, a
catabolite of t-tryptophan, while being ineffective by
itself, augmented IFN,-induced nitrite production via
both TNF-dependent and -independent mecha-
nisms. This provides further evidence for possible
connections between the tryptophan and arginine
dependent cytotoxic effector pathways in murine
macrophages.15 Binding of extracellular nucleotides,
including ATP, to purinergic receptors may increase
NO production by macrophages.TM This effect might
occur in pathological conditions where significant
amounts of ATP can be released due to cellular
damage.
An L-arginine terminal synthetic compound be-
longing to the family of hypoxanthine derivatives
enhanced IFN,-induced nitrite release from cultured
peritoneal macrophages.52 Muramyldipeptide
(MDP), a constituent of bacterial cell walls has been
shown to enhance both LPS15 and IFN-induced
12
NO production. A cytotoxic substance, isolated from
Bacillus stearothermophilus and identified as bis(2-
hydroxyethyl)trisulphide, increased NO formation by
macrophages.TM The macrophage activating tetra-
peptide tuftsin has been shown to synergize with
IFN, for NO production in murine, but not in rat
macrophages.12,155
Ligated complement receptor type 3 (CR3) and
IFN, act synergistically to induce NO production and
CR3 mediates the group B streptococcus-induced
signal for NO production in IFN,-treated
macrophages. 156 Bafilomycin A1 (BAF), an inhibitor
of vacuolar-type-H(+)-ATPases, causes an increase in
intravesicular pH and enhances nitrite release by
activated macrophages. However, the NO concentra-
tion necessary to kill parasites was higher in BAF-
exposed than in control macrophages, suggesting
that microbicidal nitrogen derivatives were less active
at alkaline pH.5: The anti-cancer drug taxol, which
blocks cell division by stabilizing microtubules,
synergized with INF,,, like LPS, to activate
macrophages for L-arginine-dependent tumour
lysis. 158 Conversely, nocodazole and colchicine, two
chemically distinct microtubule depolymerizing
agents, completely prevented LPS-induced NO pro-
duction in vascular smooth muscle cells. 159
Regulation by prostanoids and other lipids: The hy-
pothesis that platelet activating factor (PAF) acts as
auto- or paracrine up-regulator of iNOS, has been
substantiated by the finding that WEB 2086, an an-
tagonist of PAF receptors, attenuated LPS-stimulated
NO biosynthesis in cultured murine macrophages.
16
Thus, inhibition of NO induction may contribute to
the beneficial effects of PAF antagonists in
endotoxaemia.
Macrophages derived from mice fed with a diet
rich in n-3 polyunsaturated fatty acids produce more
NO2- in response to IFN, compared with
macrophages from the control group.11 Bron-
choalveolar macrophages from rats fed diets rich in
n-3 fatty acids produce significantly more NO than
macrophages isolated from n-6 polyunsaturated fatty
acids fed animals: changes in n-6-derived
prostanoids may account for these data.12
However, the regulation of iNOS activity by
arachidonic acid metabolites is still controversial.
Nitrite production by peritoneal mouse macrophages
was suppressed by phospholipase A inhibitors,
5-1ipoxygenase inhibitors and a glutathione-S-
transferase inhibitor, while inhibitors of 12- and 15-
lipoxygenase, and of cyclooxygenase were without
effect.1,14 However, Gaillard et al. reported that
PGE and dibutyryl-cyclic AMP, a stable analogue of
cyclic AMP, enhanced LPS-induced NO2- secretion by
rat Kupffer cells.65 The stimulation is maximal when
PGE is added after LPS. Cyclic AMP appeared to be
a positive signal for iNOS expression in rat vascular
smooth muscle, as well.1<: Others, however, have
reported that PGE2, the stable prostacyclin analogue
iloprost, the cyclic AMP mimetic 8-bromo-cyclic AMP
and the non-selective phosphodiestrease inhibitor
iso-butylmethylxanthine (IBMX) inhibited the LPS-
stimulated induction ofNOS in murine macrophages.
PGF2u a stable analogue of thromboxane A and the
leukotrienes B and C were without effect.<:
The hypothesis that cyclic AMP was the second
messenger in the down-regulation of NOS by
prostaglandins was reinforced by the use of drugs
which elevate the intracellular levels of cAMP (8-
bromo-cyclic AMP and IBMX). When added during
the LPS activation step, these drugs decreased NO
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synthase activity. 169 The combination of PGE and a
phosphodiesterase inhibitor, which induced a pro-
longed elevation of intracellular cyclic AMP levels,
also caused a marked reduction of the NO pro-
duction by macrophages.
171 The finding that
norepinephrine caused a dose-dependent,
adrenoceptor-mediated inhibition of the LPS-in-
duced iNOS activity in rat astrocyte cultures, but not
in the RAW 264.7 macrophage cell line,
172 is a further
indication that cyclic AMP may cause down-regula-
tion of iNOS in some, but not in all cell types.
NO also enhanced cyclooxygenase enzymatic ac-
tivity in macrophages. This suggests that in condi-
tions in which both NOS and cyclooxygenase be-
come active, there is an NO-mediated increase of the
production of pro-inflammatory prostaglandins that
may exacerbate inflammatory responses. 1:3 In respect
of this finding, and of the conflicting data on iNOS
regulation by prostaglandins, the relationships be-
tween eicosanoids and NOS deserve further investi-
gation.
Regulation of iNOS activity
Once iNOS has been expressed in macrophages,
its activity is regulated by several factors, including
auto-inactivation, and availability of substrate and
cofactors.
Auto-inactivation: NO may function as a negative
feedback modulator of iNOS activity by interacting
with the enzyme-bound haem of iNOS, which may
represent a mechanism by which the NOS pathway
in activated macrophages is turned off. 174’175 None of
14 monoclonal antibodies raised against iNOS from
rat macrophages neutralized iNOS activity, but some
of them enhanced enzyme activity through
stabilization of the enzyme. 176 Recently, a novel post-
translational and non-degradative inactivation of
iNOS has been described. LPS, after inducing iNOS,
caused macrophages to inactivate the enzyme about
3 days later,
ivy The mechanism which remains to be
identified is novel as it decreases neither the amount
nor the apparent molecular mass of the enzyme.
Bioavailability ofL-arginine: Arginine plays a pivotal
role in body protein biosynthesis, biosynthesis of
other amino acids and in the urea cycle
1,178 (Fig. 2).
Resting macrophages express arginase and the en-
zyme is up-regulated after immune activation.9,18
Arginase releases urea from L-arginine (Fig. 2) and
might modulate iNOS activity by competition for the
substrate in the microenvironment, thereby sup-
pressing macrophage-mediated cytotoxicity. Regen-
erating wounds have a decreased concentration of L-
arginine, elevated ornithine content and high
arginase activity, and it has been proposed that the
local arginine concentration could have a major ef-
fect on cell proliferation rate. 1,78 m-Hydroxy-t-
"
L-citrulline
NO, NO;, NO
FIG. 2. Pathways of L-arginine metabolism in macrophages. Constitutive
enzymes are represented by the open boxes; iNOS is only expressed after
immune stimulation of the macrophage. The bold arrows represent en-
zymes which are up-regulated upon stimulation with IFN’y and/or LPS. AS,
arginino succinate.
arginine, the intermediate in the biosynthesis of NO
from t-arginine, is a competitive inhibitor of arginase,
which may have implications in the regulation ofNO
levels in cells.8
Citrulline, the by-product of iNOS, can be recycled
to arginine by the. action of argininosuccinate
synthetase and argininosuccinate lyase1 (Fig. 2).
Induction of NOS in macrophages is accompanied
by co-induction of activity and mRNA for
argininosuccinate synthetase,
u2 the rate limiting step
in this reaction. The enhanced cellular capacity to
regenerate arginine from citrulline could play a sig-
nificant role in maintaining NO production in
111 182 183 macrophages.
Arginine is transported across cell membranes by
system y+, which is Na+-independent and pH-insen-
sitive. The system transports lysine and ornithine as
well, and competition for uptake exists among these
basic amino acids and t-arginine. Induction of NOS
by LPS is accompanied by a marked increase of y*
arginine transporter activity which involves de novo
synthesis of carrier proteins.
14 This accounts for
the accelerated uptake of arginine by murine
macrophages from culture medium. 185,16 The factors
which control LPS-induced transcription of the
arginine transporter gene and the iNOS gene diverge,
since only the latter is suppressed by glucocorticoids
in activated macrophages.4 The elevated rate of t-
arginine transport into activated cells may provide
another mechanism for sustained substrate supply
during enhanced utilization of t-arginine.
Cofactors: Various inducible and constitutive cyto-
solic co-factors are required for full iNOS activity.
These include the electron donor NADPH, 5,6,7,8-
tetrahydrobiopterin (THB), FAD, FMN and gluta-
thione. 1,3’187q89 These findings implicate a redox
cycle in which the generation of NO is facilitated.
GTP-cyclohydrolase I, the key step in the
biosynthesis of tetrahydrobiopterin, is induced by
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IFN, and LPS in human and rodent macro-
phages. 19-192 The GTP cyclohydrolase inhibitor 2,4-
diamino-6-hydroxypyrimidine, is capable of inhibit-
ing NO production by macrophages. 189a93 Sepiapterin,
a pteridine that does not occur naturally in mammals,
but which can substitute tetrahydrobiopterin via a
salvage pathway,TM led to a further increase of NO
production even in fully activated macrophages.
Phenprocoumon, an inhibitor of sepiapterin
reductase, inhibited production of NO by interfer-
ence with later steps of tetrahydrobiopterin
biosynthesis.89 Because tetrahydrobiopterin is re-
quired for the biosynthesis of neurotransmitters, a
therapeutic potential of inhibitors of tetra-
hydrobiopterin for NO-mediated pathological con-
ditions would appear to be limited. Moreover, the
addition of high amounts of tetrahydrobiopterin and
sepiapterin to activated rat macrophages led to a
marked inhibition of NO secretion, which may sug-
gest that iNOS in intact cells is susceptible to feed-
back regulatory mechanisms.93
The flavoprotein inhibitors diphenylene iodonium
and its analogues inhibit NO synthesis by mouse
macrophages, their lysates and partially purified
macrophage iNOS, 195 confirming that iNOS activity
depends on an NADPH-utilizing flavoprotein.
Proteolytic inhibitors, such as chloromethylketone
derivatives, which covalently bind to the active site
of serine proteases, can decrease cytotoxicity and
nitrite production by both mouse and rat
macrophages. 196,97 They have been shown to be
effective after induction of the enzyme. 196 As these
agents reduce glutathione levels in mononuclear
cells198 the inhibition might be due to depletion of
intracellular thiol pools and hence glutathione, one
of the co-factors of the iNOS.
100
eo
hydrocortisone
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FIG. 3. Concentration dependent inhibition of the LPS-induced nitrite pro-
duction in rat pulmonary macrophages by either dexamethasone or
hydrocortisone. Data from Jorens et aL, 1991. 4,, Hydrocortisone; B,
dexamethasone.
Inhibitors of iNOS induction
Glucocorticoids: Corticosteroids are potent suppres-
sors of iNOS induction in macrophages, 184,199,2 (Fig.
3) without influencing the induction of the L-arginine
transporter y+.184 None of the different gluco-
corticoids used has any effect once the enzyme has
been expressed,s5,199 The underlying mechanism is
receptor-mediated, since addition of equimolar con-
centrations of a partial agonist or a full antagonist of
the glucocorticoid receptor partially reversed the
action of these glucocorticoids. 199’2 At present it is
unclear whether transcription of the iNOS gene itself,
a transcription factor or a protein which degrades
iNOS mRNA is controlled by a glucocorticoid
receptor response element. Dexamethasone also
blocked IFN,-induced down-regulation of the
mannose receptor expression on macrophages, at
least partially, by inhibition of the IFN,-mediated
induction of NO production.
22
Miscellaneous inhibitors ofiNOS induction: Co-incu-
bation of murine peritoneal macrophages with mast
cell granules during LPS activation dose-dependently
inhibited macrophage-mediated tumour cell lysis,
and this was associated with a decreased NO produc-
tion.23 The inhibitory effect was not due to histamine
or serotonin present in the mast cell granules.
Cloricromene, a coumarin derivative, which has been
found to increase the survival of rats injected with
lethal doses of LPS, inhibited the induction but not
the activity of the enzyme.24 Therefore, these agents
may have anti-inflammatory/immunosuppressive ef-
fects. Pharmacological agents inhibiting iNOS induc-
tion in activated macrophages also include the
bisbenzylisoquinoline alkaloids, anti-inflammatory
constituents of plants of the families
Menispermaceae and Ranunculaceae, which have
been used as folk remedies inJapan and China.25 All-
trans-retinoic acid, a retinoid with growth-inhibiting
and differentiation-inducing properties, inhibited
TNF and NO production in peritoneal
macrophages.2
High concentrations of some dihydropyridine Ca
2/
channel antagonists, such as nifedipine, as well as a
ca channel agonist inhibited the induction of iNOS
in phagocytic cells. 27, 208 It is unlikely that the effect
of nifedipine was dependent on Ca2+ channel antago-
nism, as two other Ca
2/ antagonists (verapamil and
diltiazem) and reduction of extracellular Ca2+ with
EGTA exerted only a marginal inhibitory effect.27,28
Inhibitors of iNOS activity
Substrate analogues: After the discovery of the inhi-
bition of NO formation by NG-monomethyl-t
arginine (L-NMMA),,2,29 other t-arginine analogues,
i.e., t-NG-nitroarginine (t-NNA), its methyl ester
(t-NAME) and N-iminoethyl-t-ornithine (t-NIO),
2
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have been shown to inhibit NOS by competition
with L-arginine (reviewed by Moncada et al.
and Nathan3). Previous studies have established
that iNOS and cNOS may vary in their susceptibility
to inhibitory i-arginine analogues.
211 The
structure of the N substituent appears to determine
isoform selectivity.
21-4 t-NNA appeared to be
about 300 times less potent as an inhibitor of
mouse macrophage iNOS when compared with
bovine brain cNOS,
214 whereas t-NMMA is more
potent than -NNA as inhibitor of macrophage
iNOS.21 The irreversible inactivation of iNOS by
t-NMMA requires NADPH-dependent hydroxy-
lation. 211’215 Conversely, -NNA was significantly more
potent than L-NMMA as inhibitor of cNOS
in vascular endothelial cells. This could be due to
the significant metabolism of t-NMMA, but not
t-NNA, to t-citrulline in the endothelial cell. t-
citrulline is subsequently transformed to t-arginine.26
This indicates that L-NMMA may serve as a supply of
substrate, as well as an inhibitor ofNOS under in vivo
conditions, t-NIO is a potent irreversible inhibitor of
both isoforms.21
These t-arginine analogues are taken up by
macrophages. This is mediated by both the cationic
y+ transporter (t-NMMA, t-NIO) and a neutral amino
acid transporter (-NNA, L-NAME). 217,219 t-Arginine
transport by system y+ is reduced by I-NMMA and t-
NIO, but not affected by t-NNA and L-NAME. 218,219 A
neutral amino acid transporter (Fig. 2), with low
substrate specificity and insensitive to LPS, mediated
the uptake of t-citrulline, t-NNA and t-NAME.’8
Hence, these arginine analogues appear to be not
specific for NOS, and may interfere with transport or
other aspects of t-arginine metabolism.
The effects of guanidines and uraemic com-
pounds, endogenous NOS inhibitors which may
accumulate in renal failure,= have been tested on
NO production in macrophages. Aminoguanidine, a
bifunctional molecule contairiing the guanido group
of t-arginine linked to hydrazine, inhibits iNOS
in pancreatic B cells, macrophages, and
endothelium-denuded blood vessels of LPS-
treated rats and has little effect on cNOS0221-224
N,N’-diaminoguanidine, though being less potent
than aminoguanidine as inhibitor of iNOS, appeared
to be more selective without effect on cNOS.
1,1-Dimethylguanidine inhibited both iNOS
and cNOS, with a potency comparable with - NMMA.TM From these data it would appear to be
feasible to develop iNOS specific inhibitors, which
would be of great help as pharmacological tools for
the elucidation of the role of iNOS in pathological
conditions.
Inhibition via cofactors: Flavoprotein binders,
calmodulin binders, haem binders and depletors of
tetrahydrobiopterin all have inhibitory activities.
Catalase inhibits the activity but not the induction of
the enzyme in macrophages stimulated with IFN.
225
The inhibition by catalase is reversed in a dose-
dependent manner by the addition of the cofactor
tetrahydrobiopterin. These results suggest that hy-
drogen peroxide, which is broken down by the
catalase enzyme, may interfere with NO production
by affecting the levels of cofactor needed for its
synthesis.
Miscellaneous inhibitors of iNOS: Some naturally
occurring inhibitors include a 5000 MW protein re-
covered from saliva of the Lyme disease vector Ixodes
dammin2 and phosphatidyl serine released by
mammary tumour cells.227 Taurine chloramine, a
naturally occurring derivative of taurine, one of the
most abundant intracellular free amino acids present
in mammalian tissues, inhibits NO secretion and
iNOS activity in activated macrophages.
228 This sug-
gests a mechanism through which taurine supple-
mentation may protect against oxidant-induced tis-
sue damage as taurine chloramine is formed by
chlorination of taurine by the halide-dependent
myeloperoxidase system. Other inhibitors include 3-
and 4-amino-l,2,4-triazole, inhibitors of catalase and
peroxidases,229 indazoles,2 spermineTM and certain
antifungal imidazoles.22
NO as a regulator ofmacrophagefunction: NO may
curtail macrophage energy metabolism and viability
(vide supra), but information on the role of NO as
modulator of cytokine production in effector cells is
relatively scant. A donor of exogenous NO has been
shown to elevate cyclic GMP levels in human
macrophages.23 Correlations between nitrite release
and biosynthesis of cytokines by peritoneal
macrophages were absent.TM Physiological levels of
NO, as produced by activated mouse macrophages,
can selectively down-regulate IL-3 production by
spleen cells from contact-sensitized mice, while leav-
ing IL-2 activity unaffected.25 NO produced
endogenously by rat Kupffer cells inhibits the syn-
thesis of IL-6 by these cells in an autocrine way.2
NO also inhibits macrophage expression of the
major histocompatibility complex class II antigen Ia,
which may prevent excessive NO production by
inhibiting secretion of IFN, by T-cells after inhibition
of antigen presentation.2: The ability of anti-Ia anti-
bodies, which may mimic the effect of T-cells, to
induce NO production in macrophages suggests that
MHC class II molecules act as transmembrane signal
transducers finally leading to induction of NON.82
Exposure of primed macrophages to NO-generat-
ing compounds results in inhibition of both the
consumption of tryptophan and formation of its
metabolite kynurenine in the culture medium by
inhibiting the haem-containing enzyme indoleamine-
2, 3-dioxygenase, the other inducible and amino acid
dependent effector pathway with antimicrobial and
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antitumour activities in macrophages. 238 Thus NO
may have an important role as an immuno-
modulatory as well as effector and autocrine mol-
ecule in the immune system.
Is NO formed by human macrophages?
Reactive nitrogen intermediates are important host
defence activities of mouse and rat macrophages, but
conclusive proof for NO formation from t-arginine by
human macrophages is lacking. Indeed, human
monocytes and macrophages acquire cytostatic and
anti-microbial activity independent of NO190’192’239-242
and fail to produce nitrite after stimulation with
different cytokines.24245 These results suggest that
the t-arginine dependent generation of reactive nitro-
gen intermediates is a species-restricted macrophage
mechanism unlikely to participate in the intracellular
antimicrobial activity of IFNy-stimulated human
mononuclear phagocytes. Tetrahydrobiopterin bio-
synthesis is induced in human macrophages19-192 and
deficiency of tetrahydrobiopterin, a cofactor for NOS
activity, cannot explain the inability of human
macrophages to generate NO. Even exogenous ad-
ministration of tetrahydrobiopterin failed to elicit NO
biosynthesis in human macrophages. 246 Still, two
questions remain to be resolved. First, it is unclear
whether the Griess reaction, often employed to de-
tect NO2- production by macrophages, is sufficiently
sensitive. Secondly, it is unclear whether the
cytokine profiles used so far to stimulate human
macrophages are incomplete and/or distinct from the
rodent systems.
Indeed, several lines of indirect evidence suggest
the existence of iNOS in human cells. 247 Elevated
nitrate levels are found in the plasma and urine of
individuals treated with the cytokine It-2,
248 and in
patients suffering from infections or sepsis, 1,249 condi-
tions known to induce IFNy, TNF0 and IL-1 in vivo.
CAa+-independent NOS activity and iNOS mRNA ex-
pression have recently been demonstrated in human
primary hepatocytes following treatment with LPS
and three cytokines,25 a megakaryocyte cell lineTM
and a human colonic epithelial cell line. 252
Moreover, a number of in vitro studies have pro-
vided circumstantial evidence for NO generation by
human mononuclear cells. Human mononuclear
cells inhibit platelet aggregation by releasing a nitric
oxide-like factor.253 TNF and GM-CSF stimulate
human monocytes to restrict growth of Myco-
bacterium avium after incubation for several days,
dependent on the generation of nitrite. 254 A virulent
strain of Mycobacterium avium has been shown to
induce NO formation in human monocyte-derived
macrophages. 255 Human monocytes are stimulated to
release NO upon in vitro co-incubation with some
tumour cells. 256 Human alveolar macrophages are
positive for iNOS in areas of acute and chronic
inflammation, as shown by immunohistochemistry of
human lung specimens with an antibody directed
against cloned murine macrophage iNOS. 257’258 Hu-
man mononuclear cells stimulated with glycoprotein
120 of the envelope of human immunodeficiency
virus produced small amounts of nitrite. 259 Small
quantities of nitrite and citrulline were also generated
after incubation of human alveolar macrophages
with Pneumocystis carinii.2 Recently, Reiling et al.261
have isolated an iNOS-specific amplification product
from human monocytes stimulated with LPS/IFNy
prior to mRNA extraction, as detected by reverse
transcriptase polymerase chain reaction. Moreover,
analysis of human genomic DNA revealed a specific
human iNOS gene. 22,261,262 Finally, IFNy and TNF{x
were involved in the activation of the trypanocidal
activity of human monocytes through an NO de-
pendent mechanism. 119
The combined data thus suggest that iNOS activity
can be induced to some extent in human
macrophages. However, in contrast to the indole-
amine-2,3-dioxygenase effector pathway, 9’192,242 the
expression of iNOS in human macrophages requires
rather specific conditions and limited quantities of
NO appear to be generated via the t-arginine de-
pendent effector pathway.
Conclusion
In the past few years it has become clear that NO,
formed from t-arginine by inducible forms of NOS,
acts as effector molecule in the cytotoxic and cyto-
static activities of rodent macrophages. Since iNOS is
normally not constitutively expressed in resting
macrophages, transcription and translation of the
iNOS gene constitutes the first regulatory level of this
pathway. Appropriate stimuli, i.e., microbial constitu-
ents and some cytokines, trigger iNOS transcription.
Fine tuning of the induction process appears to be
complex, and priming, suppression or stimulation of
the induction may occur, depending on the cocktail
of cytokines present in the macrophage environ-
ment. Glucocorticoids inhibit NO release at this level;
they repress transcription and/or translation of the
iNOS gene. Several mechanisms govern the activity
of iNOS once it has become expressed. Auto-inacti-
vation by NO appears to curtail the life-span of active
iNOS enzyme. Availability of the substrate t-arginine
is another important mechanism of post-translational
regulation. Expression of the y/ carrier, which trans-
ports basic amino acids across the cytoplasmic mem-
brane, can be up-regulated by the same set of stimuli
that induce iNOS transcription. Up-regulation of
argininosuccinate synthetase activity, the rate limit-
ing step in the pathway that recycles t-citrulline to L-
arginine, is another mechanism to provide iNOS with
substrate. Conversely, the same set of stimuli may
cause up-regulation of arginase expression and ex-
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cretion, and remove L-arginine from extracellular and
intracellular sources, thereby competing with the y/
carrier and iNOS for the available substrate. It is still
unclear to what extent NO influences the
biosynthesis of cytokines, prostanoids and other
macrophage products, as several reports contradict
each other. However, there is little doubt that exces-
sive NO formation will eventually kill the
macrophage itself.
Despite intense, often unpublished research, dem-
onstration of the expression of iNOS activity in hu-
man macrophages remains troublesome. Inadequate
analytical procedures and/or stimuli could form an
explanation. Moreover, the role of NO in inflamma-
tory reactions, and its interactions with prostanoids
are still controversial. Important progress is, how-
ever, to be expected in these fields, once specific
pharmacological tools, i.e., substrate analogues with
selectively for the inducible isoforms of NOS, or mice
in which the iNOS has been knocked out, become
available.
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